3 most used medications on Medicare price negotiation list

The Biden administration has announced the first 10 medications that will be subject to price negotiations with Medicare under the Inflation Reduction Act. 

Advertisement

These are the three that were most commonly used by Medicare Part D patients between June 1, 2022, and May 31, according to an Aug. 29 report from CNBC

Eliquis, a blood thinner made by Bristol-Myers Squibb, was the most commonly used, with 3.7 million Medicare enrollees on the medication. 

Jardiance, a low blood sugar medication for Type 2 diabetes made by Boehringer Ingelheim, was used by 1.6 million people.

Xarelto, a blood thinner made by Johnson & Johnson, was used by 1.3 million beneficiaries. 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in ASC Coding, Billing & Collections

Advertisement

Comments are closed.